Fubotv earnings beat by $0.10, revenue topped estimates
On Wednesday, Stifel analysts maintained their Buy rating and $55 price target for AnaptysBio stock (NASDAQ: NASDAQ:ANAB), which currently trades at $23.52. According to InvestingPro data, analyst targets range from $18 to $90, with the stock showing impressive momentum, gaining over 77% year-to-date. This decision follows the release of full 28-week results from the company’s Phase 2b study of Rosnilimab for the treatment of rheumatoid arthritis.
The study results indicate that Rosnilimab shows high activity and efficacy that is competitive with second-line agents, such as JAK inhibitors. Notably, the maintenance of Clinical Disease Activity Index Low Disease Activity (CDAI LDA) among responders after 14 weeks was robust, with some patients maintaining LDA for 10 weeks post-dosing.
While certain aspects of the trial design, such as the absence of a placebo crossover, may limit direct cross-trial comparisons, the data overall support Rosnilimab’s potential as a highly active and competitive drug. The differentiation from first-generation agonists and depleters from companies like Eli Lilly (NYSE:LLY) and Johnson & Johnson can be attributed to the greater depletion of PD-1+ T-cells.
Regarding safety, there are ongoing questions about the long-term impacts of PD-1 agonism. However, the discontinuation rates due to adverse events remain low, at less than 5%. Looking ahead, the focus will be on upcoming ulcerative colitis data expected in the fourth quarter of 2025, which will guide strategic decisions for AnaptysBio.
In other recent news, AnaptysBio has reported promising results from its Phase 2b trial for the rheumatoid arthritis drug rosnilimab, which demonstrated significant efficacy and safety. The trial showed that patients achieved low disease activity and remission, with responses maintained for two months after treatment cessation. Additionally, the company is conducting a Phase 2 study for rosnilimab in ulcerative colitis, with initial data expected in the fourth quarter of 2025. Analysts from H.C. Wainwright upgraded AnaptysBio stock to Buy, citing favorable trial data and setting a price target of $38.00. Guggenheim also raised its price target for AnaptysBio shares to $90, emphasizing the company’s strong financial position and potential royalties from its collaboration with GSK. Wolfe Research maintained an Outperform rating with a $25 price target, noting the company’s undervaluation and potential in the ulcerative colitis program. TD Cowen reiterated a Buy rating, highlighting the significance of the updated trial data for rosnilimab. These developments reflect growing confidence in AnaptysBio’s research and potential market impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.